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It has been 25 years since the oligometastatic hypothesis
was formally defined and nearly a century since the first
published report of an oligometastatic patient being treated
with curative intent.1,2 Despite the passage of time, there
remains substantial debate regarding whether the oligo-
metastatic state exists and whether patients benefit from
aggressive local treatment to metastases.3 Some authors
argue that the oligometastatic state is a separate disease
entity (variously defined with upper limits of 1, 3, 5, or 10
metastases) and that such patients are amenable to curative
treatment strategies. Opposing arguments hold that these
patients with only a few metastases represent only the tail
end of a distribution of patients with widespread metastatic
disease and that aggressive treatments expose patients to
potential toxicities with little chance of benefit.4
We have now entered the era of phase 3 trials testing the
oligometastatic hypothesis. These trials are supported by
data from phase 2 randomized trials suggesting that patients
treated with ablative therapies (eg, surgery, stereotactic
ablative radiation [SABR], or radiofrequency ablation)
benefit with improved progression-free survival or overall
survival.5-9 These new phase 3 trials are attempting to
demonstrate overall survival benefits with ablative therapies
in patients with a defined number of metastases (eg, 1-3, 4-
10). Their findings will be critical to the field of oncology:
By proving or disproving the oligometastatic theory, we
will either usher in a new era of escalated treatment for
patients previously considered palliative (ie, if trials are
positive) or prove that these approaches were adopted into
practice too quickly (if the trials are negative).
This focus on the number of metastases is based on the
presumption that ablative therapies will only be beneficial
if the number of metastatic lesions is low. But what if
“oligo” does not matter? Could ablative therapies be
beneficial, in terms of important clinical outcomes,
regardless of the number of metastases, even in a patient
with 20 or 30 lesions?
Before considering this question, we must first consider
what types of ablative therapies would be possible with
large numbers of metastases. In most situations, surgery
would not be feasible. Widespread surgery to resect large
parts of several visceral organs and bones is expected to be
toxic and lead to substantial morbidity. Percutaneous ap-
proaches, such as radiofrequency ablation, microwave
ablation, and cryotherapy, are useful for anatomically
favorable locations,5,10,11 but not all sites of the body (eg,
brain or locations near major vessels) are treatable. SABR
is the best candidate for such a widespread approach
because all body sites can be treated if the doses are
appropriately reduced and attention to total body and bone
marrow dose is integrated into planning considerations. As
an example, in the ongoing phase 3 SABR-COMET-10
trial,12 patients with 4 to 10 oligometastases undergo ra-
diation preplanning before randomization to ensure that
SABR can be delivered safely. All patients thus far (n Z
18) who have undergone preplanning have passed and been
enrolled, even patients with up to 10 lung lesions (the le-
sions must be small); an example is shown in Figure 1. It is
likely that if lesions are small, it would also be possible to
devise radiation plans that meet our parameters of normal
tissue tolerance to treat liver, brain, or bone lesions in this
same patient.
Under the assumption that SABR would usually be the
best choice of modality to treat polymetastatic disease, we
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will now revisit the question of whether “oligo” matters, or
more specifically, whether it could be worthwhile to deliver
SABR to large numbers of metastases. As an analogy,
consider a theoretical drug that is useful in patients with
metastatic disease. This drug has the effect of stopping the
growth of all visible lesions for 1 year, with only modest
toxicity; at 1 year, however, the cancer resumes growth at
the previous rate, and the patient still ultimately dies of
cancer, 1 year later than would have occurred without the
drug. This would be a substantial survival improvement,
more than many approved drugs, and would be a block-
buster drug; indeed, most Food and Drug
Administrationeapproved cancer therapies gain approval
based on a lower bar than this, using surrogate endpoints
rather than overall survival.
Could SABR achieve the same toxicity and benefit
profile as this theoretical drug? Could 20 or 30 sites of
disease be safely treated, albeit with lower doses of SABR,
to achieve a definite but temporary delay in cancer growth
and lead to an improvement in overall survival? The goal of
using SABR for all lesions would not be cure, or even
permanent eradication of metastases, but merely a tempo-
rary growth arrest, an approach we would call Ablative
Radiation Therapy to Restrain Everything Safely Treatable
(ARREST).
How could ARREST of widely metastatic tumors be
achieved? It would include 4 major tenets:
1. Minimization of toxicity. Treating large areas of the
body with radiation is not a new concept and has pre-
cedent in the palliative setting. The use of hemibody
radiation for palliation of painful bone metastases has
been demonstrated to be safe and effective. Advances in
supportive agents such as 5-HT antagonists can mitigate
the systemic effects of large-volume irradiation noted in
older trials.13,14 Advances in radiation planning and
targeting techniques have vastly improved the ability to
deliver high doses of radiation with minimal toxicity.
Most randomized trials of SABR for oligometastases
Fig. 1. Axial slices of a radiation plan for stereotactic radiation therapy treatment of numerous lung metastases in the same
patient, as part of a clinical trial. The prescribed dose was 24 Gy in a single fraction to all lesions (blue colorwash indicates
regions receiving 15 Gy, green 20 Gy, orange 24 Gy, and red 28 Gy). Doses to all normal tissues were within
published safe tolerance doses. If metastases were present in other organs in this patient, design of stereotactic ablative
radiation plans targeting those lesions, while meeting published normal tissue constraints, would be feasible. (A color version
of this figure is available at https://doi.org/10.1016/j.ijrobp.2019.12.023.)
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have demonstrated low overall toxicity rates, with grade
2 or higher toxicities comparable to the control arms or
slightly higher.7-9,12 Of note, one of these trials, SABR-
COMET,6 did report 3 deaths (4.5%) that were possibly
treatment-related, warranting caution. Yet, toxicity can
be lowered further by using modest doses of SABR, and
when tumors abut important structures, target coverage
can be compromised to maintain low doses to normal
structures. As an example, in the SABR-COMET trial,
doses of 54 to 60 Gy in 3 to 8 fractions were recom-
mended for lung metastases.6 In SABR-COMET-10,
these have been reduced to doses of 20 to 35 Gy in 1
to 5 fractions.12 This approach makes radiation planning
much easier and is expected to minimize toxicity risks, at
a cost of decreased long-term local control. With the
ARREST approach, the goal would not be to eradicate
metastases with large ablative doses approaching 60 Gy,
but rather to provide a growth delay of several months
with more modest doses. As a first step, the ARREST
approach should be evaluated along the same lines as an
investigational new drug with initial phase 1 trials to
establish safety.
2. Leveraging technology for cost-effective solutions. In
many jurisdictions, the cost of SABR increases substan-
tially as additional targets are treated. A cost-effectiveness
substudy of the SABR-COMET trial found SABR to be
cost effective; in a hypothetical situation assessing cost-
effectiveness in up to 10 lesions, however, as the number
of lesions increases to 10, the benefit of SABR also needs
to increase to maintain cost effectiveness.15 An easier way
to maintain cost effectiveness would be to change funding
models for treatment of polymetastatic disease, recog-
nizing the efficiencies inherent in radiation planning when
adding extra lesions to a plan. Technologic proof of
principle for treating extended volumes and multiple
metastases safely with advanced technologies has been
demonstrated.16,17 Coupling of robust, automated lesion
detection and segmentation with efficient large-field
rotational delivery techniques is likely to improve the
cost effectiveness of SABR in the coming years. Technical
issues such as minimizing planning complexity and
treatment time may be best addressed by choosing plat-
forms that can treat multiple lesions in 1 session quickly,
rather than more complex techniques that may achieve
slightly better dose distributions at the cost of extended
time requirements for planning and treatment delivery.
3. Minimize interference with systemic therapy and
potentially improve systemic therapy efficacy. SABR
would not be expected to address micrometastatic dis-
ease, and therefore many patients who are candidates for
ARREST would likely benefit from systemic therapy.
SABR delivery should not interfere with proven sys-
temic therapies and thus must be delivered quickly. In
the SABR-COMET-10 trial, all sites must be treated
within 2 weeks to minimize interruptions in systemic
therapy. With the use of single fractions of radiation to
treat each lesion and treatment of multiple lesions per
day, only short interruptions are achievable even with
more than 10 metastases, and radiation could potentially
be delivered between cycles of systemic therapy if
shown to be safe. An ARREST approach could even
potentiate systemic therapy: The Norton-Simon hy-
pothesis holds that as overall tumor burden in the body
increases, the effectiveness of systemic therapy de-
creases. Therefore, reducing overall tumor burden could
indeed augment the effect of systemic therapy itself.18
4. Randomized trials. Carefully designed randomized trials
are necessary before any such patients are treated off-
trial. These trials should be easier to conduct than tri-
als in oligometastatic patients for 3 reasons: (1) The
situation of polymetastatic disease is much more com-
mon than oligometastatic disease; (2) it would be un-
likely that any radiation oncologists would treat off-trial,
a practice that has hampered accrual to oligometastases
trials19; and (3) sample sizes may be much smaller than
those required in oligometastatic tumors because poly-
metastatic patients would be expected to have shorter
survival, which drives down the sample size required to
find a given effect size. Inherent in such trials would be
the need to incorporate robust patient-reported out-
comes, quality-of-life measures, and toxicity stopping
rules to ensure the goals of ARREST are achieved while
minimizing risks to our patients.
Using SABR or other ablative therapies to treat widely
metastatic disease is an idea that has historically been
anathema to oncologists, because the treatment would be
considered futile when the vast majority of patients prog-
ress within months after treatment. Yet the paradigm of
delivering treatments with appreciable risks of serious side
effects, knowing that progression is inevitable, is central to
medical oncology practice. With modern radiation
oncology technologies, using SABR to treat widely meta-
static disease would be a radical departure from the tradi-
tions of oncology. However, a paradigm of using ARREST
to delay tumor progression, albeit temporarily, at multiple
tumor sites could be consistent with principles accepted in
medical oncology and could redefine the treatment of
metastatic disease.
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